Loading patent…
OwnerMichael W. Rooneyinventor
Estimating the term…
The present intention provides superoxygenating compositions that comprise hemoglobin and guanosine 3′:5′-cyclic monophosphate (cyclic GMP) generating compounds, and methods for treatment of diseases or medical conditions which utilize the superoxygenating compositions as biocolloids, i.e. hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids. The cardiac output-increasing compositions comprise a simple mixture of hemoglobin and the cyclic GMP generating compounds or hemoglobin physically or chemically coupled to the cyclic GMP generating compounds. The invention also provides time-controlled superoxygenating compositions of hemoglobin and cyclic GMP generating compounds that would be used for treatment of specific diseases or medical conditions requiring time-dependent use of biocolloids, i.e. hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids.
A hemoglobin colloid composition for use in hemodilution, blood substitution, plasma expansion or fluid resuscitation consisting of a hemoglobin-based material and a guanosine 3′:5′-cyclic monophosphate (cyclic GMP) generating compound, said hemoglobin colloid composition used for the intended purpose of producing oxygen delivery, in vivo, that is superior to that obtained with hemoglobin-based material alone, said hemoglobin colloid composition being substantially free of adverse hemodynamic effects, said hemoglobin colloid composition selectively affecting afterload relative to preload, said hemoglobin colloid composition intentionally increasing stroke volume and cardiac output with essentially no effect on heart rate.
A method for treatment of diseases or medical conditions requiring a hemodiluent, blood substitute, plasma expander, or resuscitative fluid consisting of steps:
A hemoglobin colloid composition of claim 19 or method of claim 4 further characterized by the fact that, in vivo, it:
A hemoglobin colloid composition of claim 19 or method of claim 4 further characterized by the fact that, in vivo, it:
A hemoglobin colloid composition of claim 19 or method of claim 4 further characterized by the fact that, in vivo, it:
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is a dihydropyridine further characterized by the fact that, in vivo, it provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is nicardipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is isradipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is nitrendipine or nisoldipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is nifedipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its effective half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is felodipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is amlodipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is nimodipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is lacidipine or pranidipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is benidipine that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) for periods proportional to its terminal half-life that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is a dihydropyridine-nitrovasodilator complex that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) that is more than that achieved With a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition of claim 19 or method of claim 4 wherein said cyclic GMP generator is physically or chemically coupled to said hemoglobin-based material that, in vivo, provides a timed-controlled increase in whole body oxygen delivery (milliliters of oxygen per minute) that is more than that achieved with a hemoglobin-based material alone under similar physiologic conditions.
A hemoglobin colloid composition for use in hemodilution, blood substitution, plasma expansion or fluid resuscitation consisting of a hemoglobin-based material and a guanosine 3′:5′-cyclic monophosphate (cyclic GMP) generating compound, said hemoglobin colloid composition used for the intended purpose of producing oxygen delivery, in vivo, that is superior to that obtained with hemoglobin-based material alone, said hemoglobin colloid composition being substantially free of adverse hemodynamic effects, said hemoglobin colloid composition selectively affecting afterload relative to preload, said hemoglobin colloid composition intentionally increasing stroke volume and cardiac output with essentially no effect on heart rate;
Dependencies are inferred from the claim text.